Lawyers for more than 60,000 victims who support the settlement called it “a watershed moment in the opioid crisis,” while recognizing that “no amount of money could fully compensate” victims for the damage caused by the misleading marketing of Ox圜ontin. It’s also one of only two so far with provisions for victims of the crisis to be compensated directly, with payouts from a $750 million pool expected to range from about $3,500 to $48,000. The Purdue Pharma settlement would be among the largest. That’s partly because people with substance abuse disorder found pills harder to get and turned to heroin and, more recently, fentanyl, an even more potent synthetic opioid.ĭrug companies, wholesalers and pharmacies have agreed to pay a total of more than $50 billion to settle lawsuits filed by state, local and Native American tribal governments and others that claimed the companies’ marketing, sales and monitoring practices spurred the epidemic. Opioid-related overdose deaths have continued to climb, hitting 80,000 in recent years. The drug and the Stamford, Connecticut-based company became synonymous with the crisis, even though the majority of pills being prescribed and used were generic drugs. The company pleaded guilty to misbranding the drug in 2007 and paid more than $600 million in fines and penalties. Purdue Pharma’s aggressive marketing of Ox圜ontin, a powerful prescription painkiller that hit the market in 1996, is often cited as a catalyst of a nationwide opioid epidemic, persuading doctors to prescribe painkillers with less regard for addiction dangers. “I feel like I can’t really move on while this is all hanging out in the court,” Wencus said. Even though she does not expect a payout, she wants the settlement to be finalized in hopes it would help her stop thinking about Purdue Pharma and Sackler family members, whom she blames for the opioid crisis. She initially opposed the deal with Purdue Pharma but has come around. Lynn Wencus, of Wrentham, Massachusetts, also lost a 33-year-old son, Jeff, to overdose in 2017. Her lawyer, Mike Quinn, put it this way in a court filing: “The Sackler releases are special protection for billionaires.” “Anybody in the future would be able to do the exact same thing that the Sacklers are now able to do,” she said in an interview. And by allowing the deal, it could lead to more problems. When she first heard about a potential settlement that would include some money for people like her, she signed up. It also has implications for other major product liability lawsuits settled through the bankruptcy system.īut the agreement, even with billions of dollars set aside for opioid abatement and treatment programs, also poses a moral conundrum that has divided people who lost loved ones or lost years of their own lives to opioids.Įllen Isaacs’ 33-year-old son, Ryan Wroblewski, died in Florida in 2018, about 17 years after he was first prescribed Ox圜ontin for a back injury. The legal question has resulted in conflicting lower court decisions. The issue for the justices is whether the legal shield that bankruptcy provides can be extended to people such as the Sacklers, who have not declared bankruptcy themselves. 4 over whether the agreement, part of the resolution of Purdue Pharma’s bankruptcy, violates federal law. The Supreme Court is set to hear arguments Dec. At the same time, they could potentially keep billions of dollars from their profits on Ox圜ontin sales. In exchange for giving up ownership of drug manufacturer Purdue Pharma and for contributing up to $6 billion to fight the crisis, members of the wealthy Sackler family would be exempt from any civil lawsuits. But that does not mean all the victims are satisfied. WASHINGTON - The agreement by the maker of Ox圜ontin to settle thousands of lawsuits over the harm done by opioids could help combat the overdose epidemic that the painkiller triggered.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |